Skip to main content
Clinical Trials/NCT06605417
NCT06605417
Recruiting
Not Applicable

Understanding the Transition from Normal Melanocytes to Nevus to Melanoma (NevustoMel)

Fundacion Clinic per a la Recerca Biomédica2 sites in 2 countries100 target enrollmentJanuary 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congenital Melanocytic Nevi
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Enrollment
100
Locations
2
Primary Endpoint
Molecular identity profiles
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The primary objective of this study is to identify the molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in CAYA patients with L/GCMN. The secondary objectives are:

  • To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients.
  • To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources.
  • To test pre-clinical strategies to best model and improve patient response.

Detailed Description

NevustoMel is an international multicentric retrospective cohort study with molecular and experimental design. It will involve the genomic characterization of cell-free DNA and affected tissues from patients. Methylomics and single-cell multi-omics will be used to identify co-existing molecular (transcriptional and epigenomic) states at single-cell level and will be generated from affected tissues. These results will be exploited using machine learning-assisted integration of multi-modal transcriptomics, epigenomics and spatial information. Integrated analyses of single-nucleus RNA sequencing from a selection of frozen tissues and spatial transcriptomics on formalin-fixed paraffin-embedded samples will allow the comparison of the findings to ground-state Human Developmental Cell Atlas data. Distinctions will be validated either with in situ hybridization (such as RNA sequencing) or immunostaining on test cohort tissues. These results will be complemented with in vitro functional analyses, high throughput sequencing and bioinformatic analyses.

Registry
clinicaltrials.gov
Start Date
January 1, 2024
End Date
November 30, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Fundacion Clinic per a la Recerca Biomédica
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Molecular identity profiles

Time Frame: 26 months

Molecular identity profiles of all cellular states that characterize the progression from benign nevi to malignant melanoma in children, adolescents and young adults (CAYA) patients with large/giant congenital melanocytic nevi (L/GCMN)

Secondary Outcomes

  • cfDNA profiles(26 months)
  • Improve the early diagnosis and treatment of L/GCMN(26 months)
  • Test pre-clinical strategies for L/GCMN(26 months)

Study Sites (2)

Loading locations...

Similar Trials